BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1506 related articles for article (PubMed ID: 27146448)

  • 1. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Jackson LR; Kim S; Shrader P; Blanco R; Thomas L; Ezekowitz MD; Ansell J; Fonarow GC; Gersh BJ; Go AS; Kowey PR; Mahaffey KW; Hylek EM; Peterson ED; Piccini JP
    J Thromb Thrombolysis; 2018 Nov; 46(4):435-439. PubMed ID: 30051164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
    Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
    Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
    PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
    Washam JB; Holmes DN; Thomas LE; Pokorney SD; Hylek EM; Fonarow GC; Mahaffey KW; Gersh BJ; Kowey PR; Ansell JE; Go AS; Reiffel JA; Freeman JV; Singer DE; Naccarelli G; Blanco R; Peterson ED; Piccini JP
    J Am Heart Assoc; 2018 Sep; 7(18):e008928. PubMed ID: 30371218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.
    Perino AC; Shrader P; Turakhia MP; Ansell JE; Gersh BJ; Fonarow GC; Go AS; Kaiser DW; Hylek EM; Kowey PR; Singer DE; Thomas L; Steinberg BA; Peterson ED; Piccini JP; Mahaffey KW
    J Am Heart Assoc; 2019 May; 8(9):e011205. PubMed ID: 31023126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
    Black-Maier E; Kim S; Steinberg BA; Fonarow GC; Freeman JV; Kowey PR; Ansell J; Gersh BJ; Mahaffey KW; Naccarelli G; Hylek EM; Go AS; Peterson ED; Piccini JP;
    Clin Cardiol; 2017 Sep; 40(9):746-751. PubMed ID: 28543401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.